BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

524731

JENBURPH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

JENBURKT PHARMACEUTICALS LTD. Share Price Update

As of the latest trading session, JENBURKT PHARMACEUTICALS LTD. share price is currently at ₹ 1040, which is up by ₹ 7.25 from its previous closing. Today, the stock has fluctuated between ₹ 967.85 and ₹ 1043.00. Over the past year, JENBURKT PHARMACEUTICALS LTD. has achieved a return of 39.74 %. In the last month alone, the return has been 1.75 %. Read More...

JENBURKT PHARMACEUTICALS LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    458.30

  • P/E Ratio (TTM)

    14.59

  • Beta

    0.98

  • Book Value / share

    357.46

  • Return on equity

    19.44%

  • EPS (TTM)

    71.16

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    6.51

info icon alternate text

JENBURKT PHARMACEUTICALS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 36.89
Operating Expense 28.96
Net Profit 6.51
Net Profit Margin (%) 17.64
Earnings Per Share (EPS) 14.75
EBITDA 10.39
Effective Tax Rate (%) 31.65
Particulars SEP 2024 (Values in Cr)
Revenue 41.22
Operating Expense 30.55
Net Profit 9.60
Net Profit Margin (%) 23.28
Earnings Per Share (EPS) 21.75
EBITDA 13.28
Effective Tax Rate (%) 23.32
Particulars JUN 2024 (Values in Cr)
Revenue 32.54
Operating Expense 23.88
Net Profit 7.42
Net Profit Margin (%) 22.80
Earnings Per Share (EPS) 16.80
EBITDA 10.69
Effective Tax Rate (%) 26.34
Particulars MAR 2024 (Values in Cr)
Revenue 38.84
Operating Expense 29.66
Net Profit 7.88
Net Profit Margin (%) 20.28
Earnings Per Share (EPS) 17.86
EBITDA 11.04
Effective Tax Rate (%) 23.91
Particulars DEC 2023 (Values in Cr)
Revenue 35.66
Operating Expense 29.16
Net Profit 5.40
Net Profit Margin (%) 15.14
Earnings Per Share (EPS) 12.25
EBITDA 8.54
Effective Tax Rate (%) 31.12
Particulars MAR 2024 (Values in Cr)
Revenue 141.97
Operating Expense 111.46
Net Profit 25.98
Net Profit Margin (%) 18.29
Earnings Per Share (EPS) 58.86
EBITDA 37.79
Effective Tax Rate (%) 26.15
Particulars MAR 2023 (Values in Cr)
Revenue 136.75
Operating Expense 109.01
Net Profit 24.61
Net Profit Margin (%) 17.99
Earnings Per Share (EPS) 53.90
EBITDA 35.48
Effective Tax Rate (%) 25.13
Particulars MAR 2022 (Values in Cr)
Revenue 123.98
Operating Expense 99.05
Net Profit 22.30
Net Profit Margin (%) 17.98
Earnings Per Share (EPS) 48.58
EBITDA 32.20
Effective Tax Rate (%) 25.34
Particulars MAR 2021 (Values in Cr)
Revenue 109.29
Operating Expense 91.96
Net Profit 16.50
Net Profit Margin (%) 15.09
Earnings Per Share (EPS) 35.96
EBITDA 24.15
Effective Tax Rate (%) 23.75
Particulars MAR 2020 (Values in Cr)
Revenue 118.89
Operating Expense 101.98
Net Profit 14.87
Net Profit Margin (%) 12.50
Earnings Per Share (EPS) 32.40
EBITDA 23.97
Effective Tax Rate (%) 29.65
Particulars MAR 2024 (Values in Cr)
Book Value / Share 328.42
ROE % 19.44
ROCE % 25.67
Total Debt to Total Equity 0.01
EBITDA Margin 26.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 277.32
ROE % 20.53
ROCE % 26.04
Total Debt to Total Equity 0.04
EBITDA Margin 25.95
Particulars MAR 2022 (Values in Cr)
Book Value / Share 255.77
ROE % 20.66
ROCE % 25.94
Total Debt to Total Equity 0.05
EBITDA Margin 25.97
Particulars MAR 2021 (Values in Cr)
Book Value / Share 214.55
ROE % 18.49
ROCE % 22.77
Total Debt to Total Equity 0.05
EBITDA Margin 22.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 174.32
ROE % 18.89
ROCE % 24.71
Total Debt to Total Equity 0.07
EBITDA Margin 20.16
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 79.19
Total Assets 165.09
Total Liabilities 165.09
Total Equity 144.94
Share Outstanding 4413300
Price to Book Ratio 2.10
Return on Assets (%) 15.73
Return on Capital (%) 17.92
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 53.80
Total Assets 141.81
Total Liabilities 141.81
Total Equity 122.38
Share Outstanding 4413300
Price to Book Ratio 2.40
Return on Assets (%) 17.35
Return on Capital (%) 19.71
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 49.02
Total Assets 142.94
Total Liabilities 142.94
Total Equity 117.38
Share Outstanding 4589378
Price to Book Ratio 2.22
Return on Assets (%) 15.59
Return on Capital (%) 18.1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 56.50
Total Assets 121.18
Total Liabilities 121.18
Total Equity 98.46
Share Outstanding 4589378
Price to Book Ratio 1.86
Return on Assets (%) 13.61
Return on Capital (%) 16.15
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 57.69
Total Assets 104.30
Total Liabilities 104.30
Total Equity 80.00
Share Outstanding 4589378
Price to Book Ratio 1.82
Return on Assets (%) 14.25
Return on Capital (%) 17.82
Particulars MAR 2024 (Values in Cr)
Net Income 25.97
Cash from Operations 16.38
Cash from Investing -0.58
Cash from Financing -7.07
Net change in Cash 0.46
Free Cash Flow 18.94
Particulars MAR 2023 (Values in Cr)
Net Income 24.60
Cash from Operations 25.27
Cash from Investing 2.61
Cash from Financing -21.04
Net change in Cash -1.37
Free Cash Flow 27.38
Particulars MAR 2022 (Values in Cr)
Net Income 22.29
Cash from Operations 16.83
Cash from Investing -1.20
Cash from Financing -5.53
Net change in Cash 2.53
Free Cash Flow 19.88
Particulars MAR 2021 (Values in Cr)
Net Income 16.50
Cash from Operations 25.29
Cash from Investing -18.78
Cash from Financing -0.71
Net change in Cash -0.04
Free Cash Flow 26.43
Particulars MAR 2020 (Values in Cr)
Net Income 14.86
Cash from Operations 20.48
Cash from Investing -2.87
Cash from Financing -10.83
Net change in Cash 1.30
Free Cash Flow 25.03
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2959.45 58.70 29.97 50134.87 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

JENBURKT PHARMACEUTICALS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1038.40 0.54 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 1048.90
  • 26 Days 1050.00
  • 10 Days 1057.80
  • 50 Days 1054.00
  • 12 Days 1058.10
  • 100 Days 1070.10
  • 20 Days 1053.20
  • 200 Days 1043.50
1039.82 PIVOT

First Support

1013.03

First Resistance

1059.53

Second Support

993.32

Second Resistance

1086.32

Third Support

966.53

Third Resistance

1106.03

RSI

47.70

ADX

39.71

MACD

8.09

Williams % R

-61.25

Commodity Channel Index (CCI)

-79.08

Date

2025-04-30

Week

848.00

Same Day

962.00

Month

831.00

1 Year

0.99

3 Year

0.60

Over 1 Month

1.75%

down

Over 1 Year

39.74%

down

Over 3 Months

-7.85%

down

Over 3 Years

20.38%

down

Over 6 Months

8.25%

down

Over 5 Years

24.76%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

JENBURKT PHARMACEUTICALS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
53.2%
Promoter Holdings
46.67%
FII
0.0%
DII
0.11%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Bhuta Holdings Private Limited 616128.0 (13.96%) Shareholding of Promoter and Promoter Group
Late. Jayshree Uttam Bhuta 536480.0 (12.16%) Shareholding of Promoter and Promoter Group
Kalindi Hemendra Bhuta 399700.0 (9.06%) Shareholding of Promoter and Promoter Group
Ashish Uttam Bhuta 261127.0 (5.92%) Shareholding of Promoter and Promoter Group
Nirmala Vinodkumar Daga 145493.0 (3.3%) Public Shareholding
Mahesh Harshad Bhuta 67860.0 (1.54%) Shareholding of Promoter and Promoter Group
Ranjeet Singh Sibia 65650.0 (1.49%) Public Shareholding
Optirational Ventures Llp 52673.0 (1.19%) Public Shareholding
Bhavika Ashish Bhuta 51637.0 (1.17%) Shareholding of Promoter and Promoter Group
Kunti Ketan Gala 51278.0 (1.16%) Shareholding of Promoter and Promoter Group
Rajiv Garg 47413.0 (1.07%) Public Shareholding
Parshva Kumar Daga 46557.0 (1.05%) Public Shareholding
Sushila Paraskumar Daga 46346.0 (1.05%) Public Shareholding
Varun Daga 45450.0 (1.03%) Public Shareholding
Bharath C Jain 45000.0 (1.02%) Public Shareholding
Kaushik Daga 45000.0 (1.02%) Public Shareholding
Riddhi Haresh Shroff 32240.0 (0.73%) Shareholding of Promoter and Promoter Group
Jagruti Ketan Bhuta 26640.0 (0.6%) Shareholding of Promoter and Promoter Group
Shivani Haresh Shroff 17000.0 (0.39%) Shareholding of Promoter and Promoter Group
Prakash H Bhuta 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

JENBURKT PHARMACEUTICALS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
19 Jul 2023 14.4 Final 20 Jul 2023 Equity shares
21 Jul 2022 12.0 Final 23 Jul 2022 Equity shares
30 Aug 2021 10.2 Final 01 Sep 2021 Equity shares
18 Mar 2020 8.1 Interim 19 Mar 2020 Equity shares
22 Jul 2019 10.2 Final 24 Jul 2019 Equity shares
23 Jul 2018 6.0 Final 25 Jul 2018 Equity shares
27 Mar 2018 3.0 Interim 28 Mar 2018 Equity shares
21 Jul 2017 8.1 Final 25 Jul 2017 Equity shares
19 Jul 2016 0.9 Final 21 Jul 2016 Equity shares
17 Mar 2016 6.3 Interim 18 Mar 2016 Equity shares
31 Aug 2015 6.3 Final 02 Sep 2015 Equity shares
03 Sep 2014 5.1 Final 05 Sep 2014 Equity shares
18 Sep 2013 4.2 Final 20 Sep 2013 Equity shares
23 Jul 2012 3.5 Final 25 Jul 2012 Equity shares
21 Jul 2011 3.5 Final 23 Jul 2011 Equity shares
21 Jul 2010 3.0 Final 23 Jul 2010 Equity shares
23 Jul 2009 1.8 Final 25 Jul 2009 Equity shares
23 Jul 2008 1.25 Final 25 Jul 2008 Equity shares
18 Jul 2007 1.25 Final 20 Jul 2007 Equity shares
10 Aug 2005 0.0 Final 12 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

JENBURKT PHARMACEUTICALS LTD. Share Price

Jenburkt Pharmaceuticals Ltd, incorporated in 1985, was formed a venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family. The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries. It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe. The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements. In addition, it has a Research & Development unit duly approved by the Ministry of Science & Technology, Government of India. Hence, the Company has strong manufacturing facilities to cater to domestic and international market.

The purpose of the Company is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. Way back in the 20th century, a visionary in the field of healthcare and philanthropic work - Shri Nandlal Mulji Bhuta laid the foundation for several groups of companies. Continuing the legacy of Shri Nandlal Mulji Bhuta, his sons Mr. Uttam N. Bhuta and Mr. Hemendra N. Bhuta founded the Company.

In 2021-22, the Company launched a new OTC division ~ Jenburkt Wellness towards better physical and mental health. The first brand launched was Zixa Strong, natural, pain relief product. Further, it launched Nervijen D3 tablets in 2022-23.

Parent organization Indian Private
NSE symbol [-]
Founded 1985
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Jenburkt Pharmaceuticals Ltd?

Answer Field

The share price of Jenburkt Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 1038.40.

What is the Market Cap of Jenburkt Pharmaceuticals Ltd?

Answer Field

The market cap of Jenburkt Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 4,58.30 Cr. as of now.

What is the 52 Week High and Low of Jenburkt Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Jenburkt Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 1375.00 and ₹ 730.00.

How to Buy Jenburkt Pharmaceuticals Ltd share?

Answer Field

You can trade in Jenburkt Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Jenburkt Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 39.74%.

What is the Current Share Price of Jenburkt Pharmaceuticals Ltd?

Answer Field

Jenburkt Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 1038.40 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Jenburkt Pharmaceuticals Ltd Share?

Answer Field

The market cap of Jenburkt Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 4,58.30 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Jenburkt Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Jenburkt Pharmaceuticals Ltd share is 14.59.

What is the PB ratio of Jenburkt Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Jenburkt Pharmaceuticals Ltd share is 357.46.

How to Buy Jenburkt Pharmaceuticals Ltd Share?

Answer Field

You can trade in Jenburkt Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Jenburkt Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Jenburkt Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Jenburkt Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|